海南医科大学学报

目的:观察应用拜新同联合安博诺治疗中重度高血压的有效性和安全性。方法:将120例中重度高血压依据就诊顺序分为A组(拜新同联合安博诺组)、B组(拜新同组)、C组(安博诺组)3组,观察血压、临床症状减轻情况来判断疗效,观察副作用发生情况来判断安全性。结果:3组服药后测血压与服药前比较均有明显改善,A组较B组、C组血压控制更平稳、降压起效更快(P<0.05);两组治疗前后血钾(K)、血糖(GLU)、总胆固醇(TC)、甘油三脂(TG)水平比较无统计学差异(P>0.05);A组治疗后血肌酐(Cr)、尿酸(UA)水平明显低于B、C组,组间比较差异显著(P<0.05)。结论:拜新同联合安博诺对中重度高血压病疗效确切,值得临床推广应用。

Objective: To observe the effectiveness and safety of Adalat in combined with Ann Bono in the treatment of moderate and severe hypertension. Methods: A total of 120 patients with moderate and severe hypertension were included in the study and divided into group A( Adalat in combined with Ann Bono group),group B( Adalat group),and group C( Ann Bono group). The efficacy was evaluated through the blood pressure and clinical symptoms. The safety was estimated through the adverse reactions. Results: After medication,the blood pressure in the three groups was significantly improved when compared with that before medication;compared with that of group B and group C,the blood pressure controlling of group A was more significantly steady and the blood pressure reducing effect was more significantly rapid( P < 0. 05). There was no significant differences between the two groups in terms of serum kalium( K),glucose( GLU),total cholesterol( TC),and triglyceride( TG) before and after treatment( P > 0. 05). The serum creatinine( Cr) and uric acid( UA) levels after treatment in group A were significantly lower than those in group B and group C( P< 0. 05). Conclusions: Adalat in combined with Ann Bono in the treatment of moderate and severe hypertension has an accurate efficacy; therefore,it deserves to be widely recommended in the clinic.